Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting
Open Access
- 1 October 1994
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 344 (8927) , 914-918
- https://doi.org/10.1016/s0140-6736(94)92269-1
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Failure of Aspirin plus Dipyridamole To Prevent Restenosis after Carotid EndarterectomyAnnals of Internal Medicine, 1992
- Amputation or arterial reconstruction?The Lancet, 1992
- A dilemma for the 1990s. Choosing appropriate experimental animal model for the prevention of restenosis.Circulation, 1992
- Effect of low molecular weight heparin on intimal hyperplasiaBritish Journal of Surgery, 1991
- Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: A co-operative studyBritish Journal of Surgery, 1985
- The Influence of Platelet Inhibition on the Patency of Femoro-Popliteal Dacron Bypass GraftsVascular Surgery, 1985
- A Prospective Randomized Study to Examine the Effect of Aspirin Plus Dipyridamole on the Patency of Prosthetic Femoro-Popliteal GraftsVascular Surgery, 1984
- A Platelet-Inhibitor-Drug Trial in Coronary-Artery Bypass OperationsNew England Journal of Medicine, 1982
- Secondary Femoropopliteal ReconstructionAnnals of Surgery, 1981
- Suppression by heparin of smooth muscle cell proliferation in injured arteriesNature, 1977